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Abstract
Background—Testing for patients at risk for hepatitis C virus (HCV) infection is recommended, 
but it is unclear whether providers adhere to testing guidelines. We aimed to measure adherence to 
an HCV screening protocol during a multifaceted continuous intervention.
Subjects and Methods—Prospective cohort design to examine the associations between 
patient-level, physician-level, and visit-level characteristics and adherence to an HCV screening 
protocol. Study participants included all patients with a visit to 1 of the 3 study clinics and the 
physicians who cared for them. Adherence to the HCV screening protocol and patient-level, 
physician-level, and visit-level predictors of adherence were measured.
Results—A total of 8981 patients and 154 physicians were examined. Overall protocol 
adherence rate was 36.1%. In multivariate analysis, patient male sex (odds ratio [OR] = 1.18), new 
patient (OR = 1.23), morning visit (OR = 1.32), and patients’ preferred language being non-
English (OR = 0.87) were significantly associated with screening adherence. There was a wide 
variation in overall adherence among physicians (range, 0%–92.4%). Screening adherence 
continuously declined from 59.1% in week 1 of the study to 13.7% in week 15 (final week). When 
implementing complex clinical practice guidelines, planners should address physician attitudinal 
barriers as well as gaps in knowledge to maximize adherence.
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Chronic hepatitis C virus (HCV) infection affects an estimated 3.2 million persons in the 
United States,1 and it is responsible for 40% of chronic liver disease2 and the majority of 
hepatocellular carcinoma.3 Effective treatment of HCV infection is available,4–10 but the 
majority of those infected are unaware of their status.11–15 Testing for patients at risk is 
recommended,2,7,8,16–18 but guidelines are complex, and it is unclear whether providers 
adhere to these guidelines and what factors are associated with adherence. We implemented 
a multifaceted intervention to improve adherence to guidelines for HCV testing. The purpose 
of this analysis was to report on adherence to guidelines during the intervention and factors 
associated with adherence.
Evidence-based therapeutic targets are often not met,19,20 a situation known as the 
“therapeutic gap.” Although poor patient adherence has been well documented,21,22 
physician nonadherence to guidelines contributes substantially to the therapeutic gap as 
well.23,24 Despite evidence demonstrating that adherence to guidelines is associated with 
improved outcomes,25,26 physician adherence to guidelines is often poor.23,27 In the present 
study, we sought to synthesize complex guidelines for HCV testing into a single screening 
protocol and examine physician adherence to the protocol and barriers to adherence.
The guidelines for HCV screening and testing suggest testing patients with a history of 
transfusion or organ transplant prior to 1992, persons using injection drugs,2,7,16,17 those 
with HIV infection,2,7,8 those receiving hemodialysis,2,7,16,17 children of HCV-infected 
mothers,18 and persons with unexplained elevated alanine transaminase (ALT) levels.2,7,17 
In addition, it has been noted that prevalence of HCV infection is very high among patients 
with a history of alcohol abuse,28,29 sexually transmitted diseases,30–32 psychiatric 
disease,33–36 tattoos,18 and homelessness and incarceration.18 Because one barrier to 
adherence might be awareness and understanding of the guidelines, we synthesized the 
existing guidelines and literature on HCV infection risk into a single protocol for screening 
and testing. We then conducted an intervention that included educational sessions for 
providers and used chart stickers that included risk questions and reminders to test those 
with risk.
To inform the implementation of clinical practice guidelines, we examined adherence to our 
HCV screening protocol and barriers to adherence. Barriers to adherence with clinical 
practice guidelines have been classified into 3 categories: (1) knowledge-based (eg, lack of 
awareness or familiarity with guidelines), (2) attitudinal (eg, lack of agreement with 
guidelines or lack of motivation), and (3) external (eg, time or environmental barriers).27 We 
sought to minimize knowledge-based barriers to adherence with HCV testing with the 
intervention and determine whether attitudinal and/or external barriers remained. We 
hypothesized that in the setting of our continuous intervention that focused on knowledge 
barriers to adherence, attitudinal and external barriers would continue to limit adherence to 
screening and testing guidelines.
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The study was conducted at 3 community-based primary care (family medicine or internal 
medicine) clinics affiliated with Montefiore Medical Center, a university-affiliated teaching 
hospital. The 3 participating primary care clinics are large, urban clinics located in Bronx, 
New York. Each year, 54 000 adults make more than 150 000 primary care visits to the 3 
clinics. The clinic sites are located in economically depressed areas of Bronx and serve 
patients with high rates of poverty and substance use.
Study design
The study occurred during the risk-based screening phase of the Hepatitis C Assessment and 
Testing Project (HepCAT), a serial cross-sectional intervention study investigating the 
effectiveness of strategies to improve HCV screening. The study sites underwent a 
continuous intervention during the 15-week intervention phase. The study used a prospective 
cohort design with retrospective electronic medical record (EMR) review to examine the 
associations between patient-level, physician-level, and visit-level characteristics and 
adherence to guidelines.
Study population
Study patients included all patients with a primary care visit to 1 of the 3 study clinics from 
November 24, 2008, to March 6, 2009, who had not been previously tested for HCV. Study 
physicians included all physicians who cared for study patients during each of the study 
visits, including residents and attendings.
The intervention
At the beginning of the 15-week intervention phase, all providers and site staff participated 
in on-site educational sessions focused on HCV infection risk and the screening protocol. In 
addition, project staff visited each clinic twice weekly to place stickers on all progress notes, 
encourage adherence to the screening protocol, and elicit feedback from clinic staff. A risk-
based screener sticker was placed on top of each progress note (Figure 1). The screener 
prompted the physician to ask the patient 9 questions related to HCV risk. In addition, the 
physician was asked to indicate whether patients ever had an elevated ALT level (defined as 
≥20 IU/mL for female or ≥31 IU/mL for male).20 These risks were chosen on the basis of 
the Center for Disease Control and Prevention’s HCV testing recommendations, American 
Association for the Study of Liver Diseases guidelines, and other associations’ guidelines 
reported in the literature.13,14,21 Physicians were asked to complete the sticker at every 
patient visit, unless previously completed, and to order an HCV antibody test if any risk was 
identified. Patients who were already positive for HCV antibody or who had been tested 
within the last 12 months were not asked to be tested. Spanish translations of the sticker 
were available in every medical office, and laminated versions were placed in each 
provider’s mailbox. Physicians were supplied with a script (available upon request in 
English and Spanish) to help standardize and normalize the introduction of the screening 
questions. This phase was conducted from November 24, 2008, to March 6, 2009 (15 
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weeks). After the first 6 weeks of the intervention, a second educational session for 
physicians and staff was held to increase adherence with the screening protocol.
Data extraction
For research and quality improvement purposes, Montefiore Medical Center maintains a 
data replicate of its computerized Clinical Information System containing patient 
demographics, outpatient visit records, hospital records, International Classification of 
Diseases, Ninth Revision, codes, prescriptions, and laboratory test results. From this 
replicate, we extracted demographic and clinical information for each patient and the gender 
and number of patients seen for each physician. Because the data set contains only de-
identified records, informed consent was not obtained from patients or physicians; instead, a 
HIPPA-approved data use agreement37,38 was signed by all participating investigators.
Outcome variables
The primary outcomes were (1) adherence to the screening protocol and (2) accuracy of the 
information recorded on the screener. “Adherence” was defined as a nonblank screener 
submitted with any screening information recorded.
An additional aim of the study was to measure the accuracy of information recorded on the 
screener. Accuracy of information recorded on the screener was ascertained by comparing 
information recorded from the screener with data extracted from the EMR. Because we had 
both screener and EMR data on ALT levels, liver disease, and hemodialysis, the proportion 
of patients in whom the screener correctly identified a history of elevated ALT levels, liver 
disease, and hemodialysis was examined.
Independent variables/definitions
The major independent variables included patient-level, physician-level, and visit-level 
characteristics that might be associated with adherence to the screening protocol.
• Patient-level variables:
– Age. For analysis, age was dichotomized as less than 65 years versus 65 
years or more.
– Sex. Dichotomized as male and female.
– Race/ethnicity. For analysis, race/ethnicity was collapsed into 4 
categories: non-Hispanic white; non-Hispanic black or African 
American; Latino or Hispanic; and other/unknown.
– New patient. The patient was considered a new patient if the visit being 
studied was the first visit to 1 of the 3 clinics included in the study.
– Preferred language. Each patient’s preferred language is recorded in the 
EMR. For analysis, preferred language was dichotomized as English 
versus non-English.
• Physician-level variables:
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– Physician sex. Dichotomized as male and female.
– Physician volume. The total number of patients seen by each physician 
during the study period was recorded. Physicians were defined as high-
volume if the total number of patients seen was greater than the mean 
for all physicians (85 patients).
• Visit-level variables:
– Gender concordance. A visit was defined as gender concordant if the 
sex of the patient and the physician were the same and discordant if 
they were not the same.
– Morning visit. A visit was defined as a morning visit if the visit time 
was before 1 PM. All visits that occurred after 1 PM were considered 
afternoon visits.
– Busy session. A visit was defined as having occurred during a busy 
session if the physician saw more than the number of patients defined 
by the 75th percentile for all physicians’ sessions (≥9 patients for a 
morning session; ≥7 patients for an afternoon session).
Statistical analysis
The proportion of eligible patients screened is reported. Univariate and multivariate 
associations between patient-level factors (age, sex, race/ethnicity, new patient vs non new 
patient, English preferred vs non-English preferred), physician-level factors (sex, high-
volume vs low-volume), and visit-level factors (patient physician gender concordance, 
morning vs afternoon session, busy vs nonbusy session) and the primary outcome, 
successful screening, were determined. First, we constructed univariate mixed-effects 
logistic regression models to assess the associations between each factor and successful 
screening, with a physician random effect, to account for clustering of patients within 
physician. Next, we constructed a multivariable mixed-effects logistic regression model, in a 
forward stepwise fashion retaining each factor associated with the outcome (Wald statistic: P 
≤ .20), with a physician random effect, to account for clustering. Candidate variables for the 
multivariate model included each factor associated with the outcome on univariate analysis 
(Wald statistic: P ≤ .20).
To assess the variability of adherence among physicians, the proportion of patients screened 
for each physician who saw 20 or more patients during the study period was determined. To 
assess the trend of screening adherence over the 15-week study period, the rate of screening 
adherence was calculated for each week. The analysis of the trend of screening adherence 
over time was repeated, after stratifying physicians into quartiles of overall adherence.
To determine the accuracy of screener information in patients who were screened, screener-
reported ALT elevation and hemodialysis were compared with the corresponding EMR 
measures. To determine the variability of accuracy of elevated ALT reporting among 
physicians, the proportion of screeners in which ALT elevation was accurately recorded, for 
each physician with 20 or more patients with ALT elevation, was determined.
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STATA/IC software, version 10.0 (StataCorp, College Station, Texas), was used for all data 
management and statistical analyses. The institutional review boards of Boston University 
Medical Center and Montefiore Medical Center approved the study.
RESULTS
Study population/proportion screened
Data on 8981 patients and 154 physicians were examined. Overall, 3250 were screened for 
an adherence rate of 36.1%. Demographics and clinical information for the study population 
and the subset of patients who were screened are summarized in Table 1. The mean age was 
47.8 (range, 18–102) years. The study population was predominantly female (74.1%) and 
predominantly Latino (52.7%) or African American (30.4%). The physician population was 
predominantly female (64.2%) and included both residents (52.0%) and attendings (48.0%).
Factors associated with screening protocol adherence
Univariate and multivariate analyses of factors associated with screening protocol adherence 
are given in Table 2. In univariate analysis, factors associated with an increased likelihood of 
screening protocol adherence included patient male sex (odds ratio [OR] = 1.23; 95% 
confidence interval [CI], 1.11–1.38), being a new patient (OR = 1.30; 95% CI, 1.12–1.50), 
and morning visit (OR = 1.35; 95% CI, 1.22–1.50). Factors associated with a decreased 
likelihood of screening included patients’ preferred language being non-English (OR = 0.90; 
95% CI, 0.81–1.00), gender concordance between patients and physicians (OR = 0.87; 95% 
CI, 0.78–0.96), and a busy session (OR = 0.86; 95% CI, 0.75–0.97). In multivariate analysis, 
patient male sex (OR = 1.18; 95% CI, 1.05–1.32), being a new patient (OR = 1.23; 95% CI, 
1.07–1.43), and morning visit (OR = 1.32; 95% CI, 1.19–1.47) were significantly associated 
with an increased likelihood of screening protocol adherence and patients’ preferred 
language being non-English (OR = 0.87; 95% CI, 0.80–0.99) was independently and 
significantly associated with decreased odds of screening protocol adherence.
Variation among physicians with respect to screening protocol adherence
There was a wide variation among physicians with respect to screening protocol adherence. 
Among physicians who saw at least 20 patients during the study period, the median of 
physicians screened 31.8% of their patients (range, 0%–92.4%). The top quartile of 
physicians accounted for 41.8% of screens submitted (n = 1342), whereas the bottom 
quartile of physicians accounted for 7.3% of screens submitted (n = 235). Heterogeneity of 
adherence to the screening protocol among physicians is depicted in Figure 2.
Trend of screening protocol adherence over time
Screening protocol adherence declined from 59.1% in week 1 of the study to 34.6% in week 
8 (midpoint) to 13.7% in week 15 (final week; Figure 3A). Screening protocol adherence 
increased slightly from week 6 to week 7 (from 34.3% to 37.0%) after a second educational 
session designed to increase adherence, but it declined in every other week of the study 
period. After stratifying the physicians into quartiles of overall adherence, adherence for 
each quartile declined over time (Figure 3B).
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Accuracy of screening information
Of 1560 patients with elevated ALT levels documented in the EMR, and for whom a 
screener was submitted, the screener correctly identified 209 patients (13.4%). Among 
physicians who saw at least 20 patients with elevated ALT levels documented in the EMR, 
the median of physicians correctly identified 7.1% using the screener (range, 0%–70.3%; 
Figure 4).
Of 10 patients on hemodialysis documented in the EMR, and for whom a screener was 
submitted, the screener correctly identified 9 (90%). In addition, the screener identified an 
additional 12 patients as being on long-term hemodialysis.
DISCUSSION
Despite educational sessions to promote adherence, continuous presence at the study sites, 
and chart reminders placed on all charts, adherence with an HCV screening and testing 
protocol was low: 36.1% overall. In addition, we found that adherence dramatically declined 
over the 15-week intervention, from 59.1% in the first week to 13.7% in the last week of the 
intervention period. Adherence was more likely with male and new patients, as well as 
during morning visits. Adherence was less likely with patients whose preferred language 
was not English. We found a considerable variation among physicians with respect to overall 
adherence and the accuracy of screening information recorded.
Phase 3 translational research focuses on the movement of evidence-based guidelines into 
clinical practice. To tailor intervention strategies to maximize the uptake of guidelines, it is 
important to understand the barriers to adherence. Cabana et al27 have framed these barriers 
as (1) lack of knowledge, (2) attitudinal, or (3) external. In the present study, although we 
directly addressed lack of knowledge by using an educational intervention that synthesized 
existing literature, overall adherence was low, suggesting that attitudinal and external 
barriers were playing a role. We were able to measure several external factors such as 
patient-level and visit-level characteristics and found small associations between external 
factors and adherence. But these associations were small compared with the large variation 
among physicians, suggesting that attitudinal barriers predominated.
Lack of time is often cited as a barrier to following clinical guidelines.39,40 It has been 
estimated that it would take 7.4 hours per day for a primary care physician to satisfy the US 
Preventative Services Task Force recommendations.41 Despite this, we found only a modest 
association between a busy session and decreased odds of adherence to our screening 
protocol, which was not significant after adjustment for other factors. Instead, we found a 
wide variation in adherence among physicians who all worked in the same clinics and 
presumably had the same time constraints, suggesting that individual physician’s attitudes 
about the screening protocol were the primary drivers of adherence or nonadherence.
It is worth noting that there were many questions on our screener that may have been 
uncomfortable for physicians to ask their patients, including questions about intravenous 
drug use, intranasal drug use, sexual partners, homelessness, and incarceration. It is possible 
that physicians’ discomfort with these questions may have led to negative attitudes about the 
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screening protocol and decreased adherence. Our finding that male patients were associated 
with increased adherence and that physician-patient gender concordance was associated with 
decreased adherence may be evidence of this discomfort. To address this, a more 
parsimonious list of screening questions might be used. It may be, for example, that after 
assessing intravenous and intranasal drug use, further assessment of homelessness or 
incarceration does not add to the overall risk assessment. Research that examines multiple 
risk assessments simultaneously to determine which factors confer independent risk is 
warranted.
Our study also sheds light on what types of risk assessment are appropriate to ask of 
physicians during the physician-patient visit. One question on the screener asked whether 
the patient had ever had an elevated ALT level. If the physician did not know, answering this 
question would have required logging on to a clinical information system and reviewing 
laboratory results. In our study, physicians successfully performed this task only 17.3% of 
the time, with about a third of physicians never completing this task. This suggests that 
multistep tasks to assess risk are unlikely to be completed by physicians and should be 
placed elsewhere in the workflow outside of the physician-patient visit.
In conclusion, although we addressed knowledge-based barriers to implementing an HCV 
screening and testing guideline, overall adherence to the guideline was low, suggesting that 
attitudinal and external barriers remained. When implementing complex clinical practice 
guidelines, planners must address attitudinal and external barriers to maximize adherence.
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Variation in screening among physicians.
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(A) Fraction screened each study week. (B) Fraction screened each study stratified by 
physician quartile.
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Proportion of elevated alanine transaminase levels correctly identified on screener.
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Table 1
PATIENT POPULATION NOT PREVIOUSLY TESTED FOR HEPATITIS C VIRUS
Entire Population (n = 8981) Screened Population (n = 3250)
Age, mean ± SD 47.8 ± 17.7 48.1 ± 17.1
Male sex, n (%) 2330 (25.9) 906 (27.9)
Race/ethnicity, n (%)
 White 389 (4.3) 117 (3.6)
 Black 2733 (30.4) 1035 (31.8)
 Latino 4734 (52.7) 1709 (52.6)
 Other/unknown 1125 (12.5) 389 (12.0)
Insurance, n (%)
 Medicare 1029 (11.5) 384 (11.8)
 Medicaid 4609 (51.3) 1628 (50.1)
 Self 1272 (14.2) 453 (13.9)
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Table 2
FACTORS ASSOCIATED WITH SCREENING ADHERENCE
Odds Ratio (95% CI)
Univariate Analysis Multivariate Analysis
Patient-level
 Age ≥65 y 0.93 (0.82–1.06) . . .
 Male sex 1.23 (1.11–1.38) 1.18 (1.05–1.32)
 Nonwhite race 1.16 (0.91–1.49) 1.19 (0.93–1.53)
 New patient 1.30 (1.12–1.50) 1.23 (1.07–1.43)
 Non-English 0.90 (0.81–1.00) 0.87 (0.80–0.99)
Physician-level
 Male sex 1.01 (0.68–1.49) . . .
 High-volume MDa 1.42 (0.98–2.07) 1.38 (0.94–2.03)
 Resident 1.18 (0.81–1.71) . . .
Visit-level
 Morning visit 1.35 (1.22–1.50) 1.32 (1.19–1.47)
 Gender concordance 0.87 (0.78–0.96) 0.90 (0.81–1.01)
 Busy sessionb 0.86 (0.75–0.97) 0.90 (0.79–1.03)
Odds ratio calculated using mixed-effects modeling with physician random effect.
a
Greater than or equal to mean among MDs (85 over study period).
b
Nine or more patients if morning visit or 7 or more patients if afternoon visit (75th percentile)
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